Precision Manufacturing & Photonics / Medical Devices / Industrial Automation
Strategic Profile
Novanta signed a major $50 million warehouse robotics contract with a leading e-commerce company, with revenue commencing in 2026. The company is collaborating with over 10 leading humanoid robotics players across North America and Europe on multiple projects with significant content.
Cyborg Score Rationale
Q3 2025 showed bookings growth of 17% YoY with book-to-bill of 1.03x and adjusted EBITDA of $58.1M. The company reiterated product-driven growth and provided 2026 mid-single-digit organic growth expectations. While growth faces near-term headwinds from NIH funding cuts and China trade disruptions, strategic positioning in warehouse robotics and humanoid robotics represents compelling secular tailwinds.
Top Insights
Key 2026 organic growth drivers include the continued ramp of advanced surgery products, rapid deployment of robotics in warehouse automation driven by physical AI applications, and impact of new design wins across various sectors.
NIH funding cuts and broader hesitancy in life science capital spending impacted the precision medicine segment, with China delisting of a customer contributing to a weaker environment.
For full-year 2025, Novanta expects revenue of $975M–$979M, with Q4 2025 guidance of $253M–$257M.
Operating cash flow was $116.81M with free cash flow of $102.61M over the last 12 months, while gross margin is 45.09%.